Silica nanomatrix enhances immunotherapy for solid tumors
Cancer has long remained a leading cause of death worldwide and in Hong Kong, accounting for 30% of…
CAR T-cell cancer therapy to be available in SA from mid-2026
South Australia will catch up with other mainland states from mid-2026 when cutting-edge technology to treat blood cancer…
Genetic modification enhances “living drugs” for blood cancers
CAR T cells are patient-derived, genetically engineered immune cells. They are “living drugs” and constitute a milestone in…